Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'
Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'
On Aug. 15, Wells Fargo analyst Michael Turrin downgraded the rating for Snowflake from Overweight to Equal-Weight and lowered the price target from $200 to $130.On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Ally Financial Inc. (NYSE:ALLY).
Jim Cramer推荐买入Ally Financial Inc. (纽交所:ALLY)。
On July 17, Ally Financial posted stronger-than-expected quarterly earnings results.
7月17日，Ally Financial发布了超出预期的季度业绩报告。
Cramer said he is going to hold off from recommending Snowflake Inc. (NYSE:SNOW). "It's kind of like the long knives are out for those guys right now," he added.
Cramer表示，他将暂时不推荐Snowflake Inc. (纽交所:SNOW)。他补充道：“目前为止，有点像持有对他们的长刀。”
On Aug. 15, Wells Fargo analyst Michael Turrin downgraded the rating for Snowflake from Overweight to Equal-Weight and lowered the price target from $200 to $130.
8月15日，富国银行分析师迈克尔·特林将Snowflake的评级从超重降至等重，并将价格目标从200美元下调至130美元。
When asked about Royalty Pharma plc (NASDAQ:RPRX), he said, "I always thought there was going to be more to this stock than there has been. It's really been a bit of a bust."
当被问及Royalty Pharma plc (纳斯达克：RPRX)时，他说：“我一直认为这只股票会比现在好得多。它真的有点失败了。”
On Aug. 8, Royalty Pharma reported worse-than-expected second-quarter financial results. The company reported quarterly earnings of 96 cents per share which missed the analyst consensus estimate of 99 cents per share. The company reported quarterly sales of $537.00 million which missed the analyst consensus estimate of $628.26 million.
8月8日，Royalty Pharma报告了比预期更糟糕的第二季度财务业绩。公司报告每股收益为96美分，低于每股99美分的分析师共识预期。公司报告季度销售额为5,370万美元，低于分析师共识预期的6,282.6万美元。
Core Scientific, Inc. (NASDAQ:CORZ) is a "very overvalued situation, principally because of the fact that it's never made any money. But it is another play on crypto. If you like crypto, buy crypto."
Core Scientific，Inc. (纳斯达克:CORZ)是一个“非常被高估的情况，主要是因为它从未赚过钱。但它是加密货币的另一个玩法。如果你喜欢加密货币，就买入加密货币。”
On Aug. 14, Core Scientific announced that it increased its offering of convertible senior notes from $350 million to $400 million. The company has also given initial purchasers the option to buy up to an extra $60 million in notes.
8月14日，Core Scientific宣布将可转换的优先股发行规模从35000万美元增加到40000万美元。该公司还给了初始买家购买多达6000万美元债券的选择权。
Price Action:
价格行动：
- Snowflake shares fell 0.2% to settle at $127.05 on Thursday.
- Royalty Pharma shares rose 2.9% to close at $27.41.
- Core Scientific shares gained 5.2% to settle at $9.26 on Thursday.
- Ally Financial shares gained 1.3% to close at $41.61.
- 周四，Snowflake股价下跌0.2％，收于127.05美元。
- 周四，Royalty Pharma的股价上涨2.9％，收于27.41美元。
- 周四，Core Scientific的股价上涨5.2％，收于9.26美元。
- Ally Financial的股价上涨1.3％，收于41.61美元。
- Jim Cramer Recommends Buying Clorox: 'CEO Has Done Remarkable Job'
- 吉姆·克莱默推荐购买高乐氏：'CEO表现出色'